Seattle Times investigates hospital for pushing high-volume model

A wide-reaching Seattle Times probe into Providence Health’s Swedish Cherry Hill Hospital alleges administrators pushed a “high volume approach” on surgeons, lied to patients about which surgeons would perform their procedure and performed dangerous surgeries when less invasive alternatives were available.

The report, called “Quantity of Care,”  focused on changes made at Cherry Hill after it was added to Providence in 2011, with its net operating revenue increasing by 39 percent in three years thanks to these alleged practices.

Patients provided their own records as evidence. For example, Jeff Sproles spoke to reporters after post-surgery complications he experienced after a spinal fusion procedure because the surgeon had cut too deeply into his throat. By reviewing his records, it was discovered a different surgeon than Sproles had met with, performed most of the procedure.

“Who do I turn to?” Sproles said “There is nobody to go to, to say, ‘This isn’t right, this isn’t fair.’ ”

For more on the investigation, including how Cherry Hill administrators are alleged to have suppressed physicians’ concerns about these practices, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.